EP
MLYS icon

Essential Partners’s Mineralys Therapeutics MLYS Stock Holding History

Essential Partners’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$578 Hold
23
– – ﹤0.01% 2356
2026
Q2 		$621 Buy
23
+22
+2,200% +$604 ﹤0.01% 2425
2026
Q1 		$27 Hold
1
– – ﹤0.01% 2814
2025
Q4 		$36 Hold
1
– – ﹤0.01% 2678
2025
Q3 		$38 Hold
1
– – ﹤0.01% 2595
2025
Q2 		$14 Buy
+1
New +$14 ﹤0.01% 2240

Other funds holding MLYS

AP
Andera Partners Paris $176M AUM 1.8% 1-Year Est. Return
TGY2IT
Timothy G. Youngquist 2020 Irrevocable Trust Fort Myers, Florida $530M AUM 95.29% 1-Year Est. Return
Hennion & Walsh Asset Management
Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return
FIA
FNY Investment Advisers New York $402M AUM 85.34% 1-Year Est. Return
GAMMA Investing
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
Versant Capital Management
Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return
MassMutual Private Wealth & Trust
MassMutual Private Wealth & Trust Windsor, Connecticut $3.79B AUM 19.33% 1-Year Est. Return
TWD
True Wealth Design Akron, Ohio $426M AUM 16.34% 1-Year Est. Return
Farther Finance Advisors
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
IFP Advisors
IFP Advisors Tampa, Florida $5.86B AUM 20.09% 1-Year Est. Return

Essential Partners's MLYS Position: Q3 2026 in Review

Essential Partners held its Mineralys Therapeutics (MLYS) position steady in Q3 2026 at 23 shares worth $578. The position accounts for ﹤0.01% of the portfolio, ranked #2356.

Essential Partners first reported a position in MLYS in Q2 2025 and has held it in 6 quarters since. The position peaked at $621 in Q2 2026. 11 funds tracked by Wall St. Rank hold MLYS as of Q3 2026.

  • Essential Partners held 23 shares of Mineralys Therapeutics worth $578 as of Q3 2026.
  • Essential Partners left its Mineralys Therapeutics share count unchanged in Q3 2026.
  • Mineralys Therapeutics made up ﹤0.01% of Essential Partners's portfolio in Q3 2026, its #2356 holding.
  • Essential Partners first reported a position in Mineralys Therapeutics in Q2 2025 and has held it in 6 quarters since.
  • Essential Partners's Mineralys Therapeutics position peaked at $621 in Q2 2026.
  • 11 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q3 2026.

Based on Essential Partners's 13F filing for Q3 2026, filed 14 Oct 2026.